Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Shields

Showing results (291-300 of 413) with videos related to

Pageof 42
Sort By:
Jac-Antimicrobial Resistance|March 27, 2023
Impact of <i>ompk36</i> genotype and KPC subtype on the <i>in vitro</i> activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing <i>K. pneumoniae</i> clinical isolatesTara M Rogers, Ellen G Kline, Marissa P Griffith, et al.
Antimicrobial Agents and Chemotherapy|October 3, 2018
Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant RecipientsXuemei Wu, Cornelius J Clancy, Ryan M Rivosecchi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2012
Administration of voriconazole in patients with renal dysfunctionDionissios Neofytos, Lindsey R Lombardi, Ryan K Shields, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosaAva J Dorazio, Samuel L Aitken, Virginia M Pierce, et al.
Jac-Antimicrobial Resistance|October 30, 2023
Mutations in <i>ompK36</i> differentially impact <i>in vitro</i> synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing <i>Klebsiella pneumoniae</i>Tara M Rogers, Ellen G Kline, Marissa P Griffith, et al.
Journal of Rehabilitation Research and Development|July 25, 2013
Guest editorial: emergent themes from second annual symposium on regenerative rehabilitation, Pittsburgh, PennsylvaniaFabrisia Ambrosio, Michael L Boninger, Clifford E Brubaker, et al.
Stem Cell Reports|June 11, 2021
Extension of retinofugal projections in an assembled model of human pluripotent stem cell-derived organoidsClarisse M Fligor, Sailee S Lavekar, Jade Harkin, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2015
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniaeRyan K Shields, Cornelius J Clancy, Binghua Hao, et al.
Antimicrobial Agents and Chemotherapy|November 20, 2013
In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenemLouise M Oleksiuk, M Hong Nguyen, Ellen G Press, et al.
Scientific Reports|March 2, 2021
White matter microstructure relates to motor outcomes in myotonic dystrophy type 1 independently of disease duration and genetic burdenTimothy R Koscik, Ellen van der Plas, Laurie Gutmann, et al.
Pageof 42

Showing results (291-300 of 413) with videos related to

Sort By:
Pageof 42
Jac-Antimicrobial Resistance|March 27, 2023
Impact of <i>ompk36</i> genotype and KPC subtype on the <i>in vitro</i> activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing <i>K. pneumoniae</i> clinical isolatesTara M Rogers, Ellen G Kline, Marissa P Griffith, et al.
Antimicrobial Agents and Chemotherapy|October 3, 2018
Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant RecipientsXuemei Wu, Cornelius J Clancy, Ryan M Rivosecchi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 24, 2012
Administration of voriconazole in patients with renal dysfunctionDionissios Neofytos, Lindsey R Lombardi, Ryan K Shields, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosaAva J Dorazio, Samuel L Aitken, Virginia M Pierce, et al.
Jac-Antimicrobial Resistance|October 30, 2023
Mutations in <i>ompK36</i> differentially impact <i>in vitro</i> synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing <i>Klebsiella pneumoniae</i>Tara M Rogers, Ellen G Kline, Marissa P Griffith, et al.
Journal of Rehabilitation Research and Development|July 25, 2013
Guest editorial: emergent themes from second annual symposium on regenerative rehabilitation, Pittsburgh, PennsylvaniaFabrisia Ambrosio, Michael L Boninger, Clifford E Brubaker, et al.
Stem Cell Reports|June 11, 2021
Extension of retinofugal projections in an assembled model of human pluripotent stem cell-derived organoidsClarisse M Fligor, Sailee S Lavekar, Jade Harkin, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2015
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniaeRyan K Shields, Cornelius J Clancy, Binghua Hao, et al.
Antimicrobial Agents and Chemotherapy|November 20, 2013
In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenemLouise M Oleksiuk, M Hong Nguyen, Ellen G Press, et al.
Scientific Reports|March 2, 2021
White matter microstructure relates to motor outcomes in myotonic dystrophy type 1 independently of disease duration and genetic burdenTimothy R Koscik, Ellen van der Plas, Laurie Gutmann, et al.
Pageof 42